Cometriq (cabozantinib) — United Healthcare
Non-Small Cell Lung Cancer (NSCLC) with RET gene rearrangement
Initial criteria
- Diagnosis of non-small cell lung cancer (NSCLC)
- Positive for RET gene rearrangements
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Cometriq therapy
Approval duration
12 months